AU2017213473B2 - A breathable interface system for topical reduced pressure - Google Patents
A breathable interface system for topical reduced pressure Download PDFInfo
- Publication number
- AU2017213473B2 AU2017213473B2 AU2017213473A AU2017213473A AU2017213473B2 AU 2017213473 B2 AU2017213473 B2 AU 2017213473B2 AU 2017213473 A AU2017213473 A AU 2017213473A AU 2017213473 A AU2017213473 A AU 2017213473A AU 2017213473 B2 AU2017213473 B2 AU 2017213473B2
- Authority
- AU
- Australia
- Prior art keywords
- pad
- pad section
- fabric layer
- breathable dressing
- applicator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000000699 topical effect Effects 0.000 title description 3
- 239000004744 fabric Substances 0.000 claims abstract description 90
- 239000000463 material Substances 0.000 claims description 18
- 229920000642 polymer Polymers 0.000 claims description 16
- 230000005540 biological transmission Effects 0.000 claims description 14
- 239000004952 Polyamide Substances 0.000 claims description 10
- 229920002647 polyamide Polymers 0.000 claims description 10
- 229920002635 polyurethane Polymers 0.000 claims description 10
- 239000004814 polyurethane Substances 0.000 claims description 10
- 229920000098 polyolefin Polymers 0.000 claims description 7
- 229920001247 Reticulated foam Polymers 0.000 claims description 6
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 6
- 239000004677 Nylon Substances 0.000 claims description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 5
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 claims description 5
- 229920001577 copolymer Polymers 0.000 claims description 5
- 239000005038 ethylene vinyl acetate Substances 0.000 claims description 5
- 229920002313 fluoropolymer Polymers 0.000 claims description 5
- 239000004811 fluoropolymer Substances 0.000 claims description 5
- 239000004745 nonwoven fabric Substances 0.000 claims description 5
- 229920001778 nylon Polymers 0.000 claims description 5
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 5
- 239000002759 woven fabric Substances 0.000 claims description 5
- 239000006260 foam Substances 0.000 claims description 4
- 238000004891 communication Methods 0.000 abstract description 10
- 210000001519 tissue Anatomy 0.000 description 80
- 238000011282 treatment Methods 0.000 description 19
- 239000012530 fluid Substances 0.000 description 17
- 206010052428 Wound Diseases 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 230000037361 pathway Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000007767 bonding agent Substances 0.000 description 4
- 239000000017 hydrogel Substances 0.000 description 4
- 238000002803 maceration Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 239000003522 acrylic cement Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000009530 blood pressure measurement Methods 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 230000002706 hydrostatic effect Effects 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229920001169 thermoplastic Polymers 0.000 description 2
- 239000004416 thermosoftening plastic Substances 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000009581 negative-pressure wound therapy Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
Landscapes
- Media Introduction/Drainage Providing Device (AREA)
- Surgical Instruments (AREA)
Abstract
A breathable interface system including an applicator having an aperture therethrough; a drape substantially covering the applicator; a first pad section located between the drape and the applicator; a second pad section substantially covering the aperture and located between the drape and the applicator, the second pad section substantially adjacent to the first pad section; and a fabric layer located at least partially between the second pad section and the drape; and a reduced pressure conduit in communication with one of the first pad section and the fabric layer for providing reduced pressure to the aperture; wherein the drape is secured to the applicator, covering the first pad section, the second pad section, and the fabric layer in a substantially sealed environment. 1/-4 (100 lo7 tV
Description
A BREATHABLE INTERFACE SYSTEM FOR TOPICAL REDUCED PRESSURE
BACKGROUND OF THE INVENTION
1. Field of the Invention [0001] The present application relates generally to systems and methods for providing reduced pressure tissue treatment to open wounds and other tissue sites. More particularly, the present application relates to a breathable interface systems for topical reduced pressure.
2. Description of Related Art [0002] Any discussion of the prior art throughout the specification should in no way be considered as an admission that such prior art is widely known or forms part of common general knowledge in the field.
[0003] Clinical studies and practice have shown that providing a reduced pressure in proximity to a tissue site augments and accelerates the growth of new tissue at the tissue site. The applications of this phenomenon are numerous, but application of reduced pressure has been particularly successful in treating wounds and tissue sites. This treatment (frequently referred to in the medical community as negative pressure wound therapy, reduced pressure therapy, or vacuum therapy) provides a number of benefits, including faster healing, and increased formulation of granulation tissue.
[0004] Reduced pressure tissue treatment has recently been popularized by Kinetic Concepts, Inc. of San Antonio, Texas, through its commercially available VAC reduced pressure tissue treatment systems product line. In general, such reduced pressure tissue treatment systems comprise a pad-based dressing, which is applied to the tissue and is sometimes referred to as the tissue interface or the wound interface.
[0005] Current dressings, however, have several disadvantages. They are difficult to apply to small wounds, and often lead to maceration of the wound periphery. Traditionally, dressings have been rather cumbersome, limiting many patient activities. Simply sitting on or rolling onto a dressing may cause significant patient discomfort. Moreover, these actions may compress the dressing and interfere with the application of reduced pressure to a manifold at the tissue site.
2017213473 06 Jun 2019
-2SUMMARY [0006] According to one aspect of the present invention, there is provided a breathable dressing for treating tissue comprising: an applicator having an aperture; a first pad section; a second pad section positioned substantially adjacent to the first pad section; a drape substantially covering the first pad section, the second pad section, and the applicator; a fabric layer having a first portion located between the first pad section and the applicator, and a second portion located between the second pad section and the applicator and substantially covering the aperture; and wherein the fabric layer is adapted to receive a reduced pressure to be provided to the aperture.
[0007] According to another aspect of the present invention, there is provided a breathable dressing for treating tissue comprising: an applicator having an aperture; a first pad section; a second pad section substantially covering the aperture and positioned substantially adjacent to the first pad section; a drape substantially covering the first pad section, the second pad section, and the applicator; a fabric layer having a first portion located between the first pad section and the drape, and a second portion located between the second pad section and the drape; and wherein the fabric layer is adapted to receive a reduced pressure to be provided to the aperture.
[0008] According to another aspect of the present invention, there is provided a breathable dressing for treating tissue comprising: an applicator having an aperture; a porous pad; a fabric layer located between the porous pad and the applicator and substantially covering the aperture; a drape sealed to the applicator and substantially enclosing the porous pad and the fabric layer; and wherein the fabric layer is adapted to receive a reduced pressure to be provided to the aperture.
[0009] According to another aspect of the present invention, there is provided a breathable dressing for treating tissue comprising: an applicator having an aperture; a porous pad substantially covering the aperture; a drape substantially covering the porous pad and the applicator; a fabric layer located between the porous pad and the drape, wherein the drape is sealed to the applicator to substantially enclose the porous pad and the fabric layer; and wherein the fabric layer is adapted to receive a reduced pressure to be provided to the aperture.
[0010] Unless the context clearly requires otherwise, throughout the description and the claims, the words “comprise”, “comprising”, and the like are to be construed in an inclusive
2017213473 06 Jun 2019
-3sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of “including, but not limited to”.
[0011] One illustrative embodiment of the breathable interface system includes a first pad section, a second pad section, and a fabric layer, all positioned between a drape and an applicator, in addition, the dressing may include an interface component to facilitate fluid connection of a conduit to the dressing. Alternatively, a conduit may be placed in direct contact with or inserted directly into the dressing to deliver reduced pressure that is then distributed to a tissue site through the fabric layer and the pad sections.
[0012] In another illustrative embodiment, the breathable interface system may include a layer having a high moisture vapor transmission rate, which rapidly removes moisture from the periphery of the tissue site and insulates the periphery from exudate removed from the tissue site. Thus, these illustrative embodiments substantially eliminate or reduce maceration around a tissue site during reduced pressure tissue treatment, particularly around small tissue sites.
[0013] These and other illustrative embodiments also may include a fabric layer that provides additional fluid pathways that are less susceptible to collapsing under higher compressive loads, thereby improving the performance of reduced pressure tissue treatment in active patients. These additional fluid pathways also reduce the time to distribute reduced pressure to a tissue site, which enhances the effectiveness of intermittent reduced pressure tissue treatment.
[0014] One illustrative embodiment includes a breathable interface system including an applicator having an aperture therethrough; a drape substantially covering the applicator; a first pad section located between the drape and the applicator; a second pad section substantially covering the aperture and located between the drape and the applicator, the second pad section substantially adjacent to the first pad section; and a fabric layer located at least partially between the second pad section and the drape; and a reduced pressure conduit in communication with one of the first pad section and the fabric layer for providing reduced pressure to the aperture; wherein the drape is secured to the applicator, covering the first pad section, the second pad section, and the fabric layer in a substantially sealed environment.
[0015] Another illustrative embodiment includes a breathable interface system including an applicator having an aperture therethrough; a drape substantially covering the applicator; a first pad section located between the drape and the applicator; a second pad section substantially
2017213473 06 Jun 2019
-4covering the aperture and located between the drape and the applicator, the second pad section substantially adjacent to the first pad section; and a fabric layer located at least partially between the first pad section and the second pad section and the applicator; and a reduced pressure conduit in communication with one of the first pad section and the fabric layer for providing reduced pressure to the aperture; wherein the drape is secured to the applicator, covering the first pad section, the second pad section, and the fabric layer in a substantially sealed environment.
[0016] Yet another illustrative embodiment includes a breathable interface system including an applicator having an aperture therethrough; a drape substantially covering the applicator; a first pad section located between the drape and the applicator; a second pad section substantially covering the aperture and located between the drape and the applicator, the second pad section substantially adjacent to the first pad section; and a fabric layer located at least partially between the first pad section and the second pad section and the drape; and a reduced pressure conduit in communication with one of the first pad section and the fabric layer for providing reduced pressure to the aperture; wherein the drape is secured to the applicator, covering the first pad section, the second pad section, and the fabric layer in a substantially sealed environment.
[0017] Still yet another illustrative embodiment includes a reduced pressure tissue treatment apparatus for applying reduced pressure tissue treatment to a tissue site including an applicator having an aperture therethrough; a drape substantially covering the applicator; a first pad section located between the drape and the applicator; a second pad section substantially covering the aperture and located between the drape and the applicator, the second pad section substantially adjacent to the first pad section; a fabric layer located at least partially between the second pad section and the drape, wherein the drape is secured to the applicator, covering the first pad section, the second pad section, and the fabric layer in a substantially sealed environment; a reduced pressure conduit in communication with one of the first pad section and the fabric layer for providing reduced pressure to the aperture; and a reduced pressure source in communication with the reduced pressure conduit to deliver reduced pressure to the tissue site.
[0018] Other features and advantages of the illustrative embodiments will become apparent with reference to the drawings and the detailed description that follow.
- 52017213473 06 Jun 2019
BRIEF DESCRIPTION OF THE DRAWINGS [0019] FIG. 1 is an exploded view of the breathable interface system according to an illustrative embodiment of the invention;
[0020] FIG. 2 is a perspective view of the breathable interface system without a drape according to an illustrative embodiment of the invention;
[0021] FIG. 3 is a bottom view of an applicator of a breathable interface system of FIGS. 1 and 2 according to an illustrative embodiment of the invention;
[0022] FIG. 4 is cross-sectional view of the breathable interface system along lines 4-4 of FIG. 2 according to an illustrative embodiment of the invention;
[0023] FIG. 5 is cross-sectional view of the breathable interface system according to another illustrative embodiment of the invention;
[0024] FIG. 6 is cross-sectional view of the breathable interface system according to another illustrative embodiment of the invention;
[0025] FIG. 7 is a schematic diagram of a reduced pressure tissue treatment system having a breathable interface system according to an illustrative embodiment of the invention;
FIG. 8 is a chart that compares the results of pressure transmission experiments on a conventional dressing and a breathable interface system according to an illustrative embodiment of the present invention; and [0026] FIG. 9 is a chart that compares response times when subjected to intermittent application of reduced pressure under dry conditions of a conventional dressing and a breathable interface system according to an illustrative embodiment of the present invention.
DETAILED DESCRIPTION OF A PREFERRED EMBODIMENT [0027] In the following detailed description of the preferred embodiments, reference is made to the accompanying drawings that form a part hereof, and in which is shown by way of illustration specific preferred embodiments in which the invention may be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, and it is understood that other embodiments may be utilized and that logical,
-62017213473 06 Jun 2019 structural, mechanical, electrical, and chemical changes may be made without departing from the spirit or scope of the invention. To avoid detail not necessary to enable those skilled in the art to practice the invention, the description may omit certain information known to those skilled in the art. The following detailed description is, therefore, not to be taken in a limiting sense, and the scope of the present invention is defined only by the appended claims.
[0028] The term reduced pressure as used herein generally refers to a pressure less than the ambient pressure at a tissue site that is being subjected to treatment, in most cases, this reduced pressure will be less than the atmospheric pressure at which the patient is located. Alternatively, the reduced pressure may be less than a hydrostatic pressure of tissue at the tissue site. Although the terms vacuum and negative pressure may be used to describe the pressure applied to the tissue site, the actual pressure applied to the tissue site may be significantly less than the pressure normally associated with a complete vacuum. Reduced pressure may initially generate fluid flow in the tube in the area of the tissue site. As the hydrostatic pressure around the tissue site approaches the desired reduced pressure, the flow may subside, and the reduced pressure is then maintained. Unless otherwise indicated, values of pressure stated herein are gauge pressures.
[0029] The term tissue site as used herein refers to a wound or defect located on or within any tissue, including but not limited to, bone tissue, adipose tissue, muscle tissue, neural tissue, dermal tissue, vascular tissue, connective tissue, cartilage, tendons, or ligaments. The term tissue site may further refer to areas of any tissue that are not necessarily wounded or defective, but are instead areas in which it is desired to add or promote the growth of additional tissue. For example, reduced pressure tissue treatment may be used in certain tissue areas to grow additional tissue that may be harvested and transplanted to another tissue location.
[0030] Referring to FIGS. 1-3, an illustrative embodiment of a breathable interface system 100 is shown. In this embodiment, the breathable interface system 100 includes a first pad section 102, a second pad section 104, and a fabric layer 106, all positioned between a drape 108 and an applicator 110. The breathable interface system 100 generally has one end 116 that is located substantially adjacent to or over a tissue site and another end 114 that is located distally away from end 116, in one example. Nearer to end 114, the fabric layer 106 may be positioned or located at least partially between the applicator 110 and the first pad section 102. Nearer to end 116, the fabric layer 106 may be positioned or located at least partially between the second pad section 104 and the drape 108. The fabric layer 106 extends along a portion of a top surface 124 of the second pad section 104 between the second pad
2017213473 06 Jun 2019
-7section 104 and the drape 108. Once the fabric layer 106 reaches a side 120 of the second pad section 104 it transitions near the area 118 between the side 120 of the second pad section 104 and the side 122 of the first pad section 102 to extend along a portion of the bottom surface 126 of the first pad section 102 between the first pad section 102 and the applicator 110.
[0031] FIG. 2 is an illustrative embodiment of a breathable interface system 200 without the drape 108 placed on top of the first pad section 102, second pad section 104, and fabric layer 106 for illustration purposes. The fabric layer 106 can be seen extending over the top surface 124 of the second pad section 104 and beneath the bottom surface 126 of the first pad section 102. FIG. 3 is an illustrative embodiment of the applicator 110 including an aperture 302 that extends through the applicator 110 substantially near the end 116 of the applicator 110. The aperture 302 preferably is located near a tissue site to enable fluid to flow from the tissue site to the first pad section 102, second pad section 104, fabric layer 106, and reduced pressure conduit 112 of the breathable interface systems herein described.
[0032] In an illustrative embodiment, any hydrogel or bonding agent may be applied to the aperture 302 and the applicator 110 for sealing or contact purposes with a tissue site. The second pad section 104 is generally positioned to substantially cover the aperture 302, between the drape 108 and the applicator 110 as shown in FIGS. 4 and 6. In FIG. 5, the aperture 302 may be substantially covered by the fabric layer 106 as described herein. The size of the aperture 302 may vary to accommodate larger wounds, but in one embodiment, a size of about 10 to about 20 mm is advantageous for small wounds.
[0033] Referring to FIG. 4, an illustrative embodiment of the breathable interface system 100 is shown. The aperture 302 is shown disposed through the applicator 110. In addition, the breathable interface system 100 may further include an interface 402 that facilitates fluid communication between the first pad section 102 and/or fabric layer 106 and the reduced pressure conduit 112. Referring to FIG. 5, another illustrative embodiment of the breathable interface system 500 is shown. The breathable interface system 500 may include a different arrangement of the first pad section 102, second pad section 104, and fabric layer 106 between the drape 108 and the applicator 110. In this illustrative embodiment, the fabric layer 106 is located between the bottom surface 126 of the first pad section 102 and the bottom surface 128 of the second pad section 104 and the top surface 132 of the applicator 110. The first pad section 102 and second pad section 104 are located or positioned on top of the fabric layer 106. In this illustrative embodiment, the fabric layer 106 substantially covers the aperture
-82017213473 06 Jun 2019
302. Referring to FIG. 6, yet another illustrative embodiment of the breathable interface system 600 is shown. In this illustrative embodiment, the fabric layer 106 is located between the top surface 124 of the second pad section 104 and the top surface 130 of the first pad section 102 and the bottom surface 136 of the drape 108.
[0034] In any of the breathable interface systems 100, 200, 500, and 600, the reduced pressure conduit 112 may be located in direct contact with the first pad section 102 and/or the fabric layer 106. The reduced pressure conduit 112 may be placed in direct contact with the first pad section 102 or the fabric layer 106 by directly inserting it into either of the first pad section 102 or the fabric layer 106 near the end 114 of the breathable interface system 100. In another illustrative embodiment, the breathable interface systems 100, 200, 500, and 600 may further include the interface 402 as shown in FIG. 4 for facilitating the fluid communication and flow between the first pad section 102 and/or fabric layer 106 and the reduced pressure conduit 112. In yet another illustrative embodiment, the reduced pressure conduit 112 may not be in direct contact with the first pad section 102 and/or fabric layer 106, but may otherwise be in fluid communication with the first pad section 102 and/or fabric layer 106.
[0035] In one illustrative embodiment, the side 120 of the second pad section 104 extends between the top surface 124 and a bottom surface 128 of the second pad section 104. The bottom surface 128 of the second pad section 104 may have a surface area that may cover substantially all or a portion of the top surface 132 of the end 116 of the applicator 110. Additionally, the side 122 of the first pad section 102 extends between the top surface 130 and the bottom surface 126 of the first pad section 102. The bottom surface 126 of the first pad section 102 may have a surface area that may cover substantially all or a portion of the end 114 of the top surface 132 of the applicator 110.
[0036] The applicator 110 may be any size desirable to adequately provide effective covering and functionality to a tissue site as described herein. In one aspect, the applicator 110 includes a bottom surface 134 that may preferably contact the tissue site. The end 116 of the applicator 110 may have a surface area of a different shape than the end 114 of the applicator 110. For example, the surface area of the end 116 as shown in FIG. 1 shows a surface area of a substantially circular shape. Nevertheless, the shape of the end 116 of the applicator 110 may any desirable shape, symmetric, asymmetric, or otherwise, to provide the covering of a tissue site and functionality as herein described. In one illustrative embodiment, the end 114 of the applicator 110 may have a surface area that approximates a rectangular shape; however, the end 114 of the applicator 110 may also be any desirable shape,
-92017213473 06 Jun 2019 symmetric, asymmetric, or otherwise, to provide the covering and functionality as herein described.
[0037] Preferably, the bottom surface 136 of the drape 108 covers and secures the first pad section 102, fabric layer 106, and second pad section 104 to the top surface 132 of the applicator 110. In one aspect, the applicator 110 and drape 108 are sealed together substantially around the perimeter or periphery of their respective shapes. Preferably, the applicator 110 and drape 108 isolate the tissue site from its surrounding environment and maintain a reduced pressure at the tissue site when reduced pressure is applied as described herein. The applicator 110 may be secured to drape 108 with any suitable bonding agent, such as an acrylic adhesive or hydrogel. In addition, the applicator 110 may be joined to the drape 108 by other commonly known means, such as bonding, adhesives, welding, fastening, and sintering, for example. Typically, a hydrogel or other tissue-friendly bonding agent may be applied to the tissue side or bottom surface 134 of the applicator 110, which is then placed into the tissue site or in contact with the perimeter of the tissue site to secure the dressing to the tissue site.
[0038] In an illustrative embodiment, the first pad section 102 and second pad section 104 may be a material known in the art to be suitable for reduced pressure tissue treatment, the size and shape of which may be varied to accommodate tissue sites of various size and shape as described herein. Preferably, the first pad section 102 and second pad section 104 include a plurality of flow channels or pathways to facilitate the distribution of reduced pressure or fluids to or from the tissue site, in one illustrative embodiment, the first pad section 102 and second pad section 104 are porous foam that includes interconnected cells or pores that act as flow channels. In addition to the above, the first pad section 102 and second pad section 104 may be a material such as an open cell, reticulated foam that is formed from a range of polymers, including without limitation polyurethane, polyolefin, vinyl acetate, polyvinyl alcohol, and their copolymers. Additionally, the first and second pad section 102, 104 may be woven or non-woven materials, including 3-dimensional fabric structures. The pads may also be made from a sintered polymer, including materials such as sintered polyolefin, ethylene vinyl acetate, and fluoropolymer. The first pad section 102 and second pad section 104 may also be any other type of open-cell, reticulated foam, such as GranuFoam® and Whitefoam™ that are manufactured by Kinetic Concepts, Inc. of San Antonio, Texas. If open-cell foam is used, the porosity may vary, but is preferably about 400 to 600 microns. Alternatively, gauze or any other material suited to a particular biological application may be used to construct first pad section 102 and second pad section 104. In a certain illustrative embodiment, first pad section 102 and
- 102017213473 06 Jun 2019 second pad section 104 may be constructed as a single, unitary pad. In another illustrative embodiment, first pad section 102 and second pad section 104 may be a multi-component or multi-layered pad section. Preferably, the thicknesses of the first pad section 102 and second pad section 104 is from about 1 mm to about 50 mm, and in one implementation from about 5 mm to about 20 mm, although any thicknesses may be used.
[0039] In an illustrative embodiment, the fabric layer 106 may be a woven or non- woven fabric material known in the art, the size and shape of which may be varied to accommodate tissue sites of various size and shape as described herein. It may be constructed from any fiber material that maintains its structural integrity when exposed to fluids, such as polyamide, polyolefin, nylon, polyester, a polyamide coated with polyurethane, any polymeric mesh, a nonwoven (air layed) melt blown polymer, or flexible sintered polymer. The fabric layer 106 may also be a fabric covered with adhesive or hydrogel to facilitate bonding to the tissue site, where the fabric layer 106 extends beyond the applicator 110. The material may be woven together to form a layer of appropriate dimensions, or it may be any type of open cell mesh construction of appropriate dimensions. As illustrated in FIG. 1, the fabric layer 106 may also be folded and include stitching 140 to provide additional channels and structural support. A folded fabric layer may be stitched lengthwise down the middle, as depicted in Figure 2, around the edges, or any combination thereof. As an alternative to stitching, a folded fabric layer may be secured with an acrylic adhesive or any other suitable bonding agent. The fabric layer 106 may also include several overlapping layers joined together by any known means. The thicknesses of the fabric layer 106 may be from about 1 mm to about 50 mm, or alternatively about 5 mm to about 20 mm, although any thicknesses may be used.
[0040] The drape 108 may be a flexible material having a sufficiently high moisture vapor transmission rate (MTVR) to preclude tissue maceration, typically greater than 600 mg/m2/day. In one aspect, plastics and thermoplastics are an example of suitable materials for the drape 108. And like the drape 108, the applicator 110 generally is constructed from any flexible material having a sufficiently high MTVR to preclude maceration of the tissue site, such as plastics and thermoplastics.
[0041] The reduced pressure conduit 112 may represent any conduit tubing, line, or path through which a gas, liquid, gel, or other fluid may be carried, and may have more than one internal lumen. While the reduced pressure conduit 112 may be inflexible, it is preferred that it be flexible enough for ease of use and comfort for a patient. The reduced pressure conduit is
- 11 2017213473 06 Jun 2019 configured for connection to a reduced pressure source to provide delivery of reduced pressure.
[0042] In an illustrative embodiment, the breathable interface systems 100, 200, 500, and 600 may be lightweight, low-profile interface systems for low-severity, small tissue sites, but the principles are readily extendable by a person of ordinary skill in the art to larger, more extensive tissue sites, as well as numerous other types of tissue treatments.
[0043] Referring again to FIGS. 1-6, the aperture 302 is placed over a tissue site and the reduced pressure source 704 delivers a reduced pressure through the reduced pressure conduit 112 to the breathable interface systems 100, 200, 500, and 600. The aperture 302 may be a single aperture as shown, or any number or plurality of holes, openings, apertures, slits, or the like desirable for providing distribution of reduced pressure and fluid transmission between the tissue site and the first pad section 102, second pad section 104, and fabric layer 106. As described above, the first pad section 102 and second pad section 104 may include pathways or channels that permit the reduced pressure to be distributed throughout the breathable interface systems 100, 200, 500, and 600, and that permit fluids to be removed from a tissue site through the aperture 302. The weave or mesh structure of the fabric layer 106 provides additional fluid pathways that are less susceptible to collapsing under compressive loads that may be applied to the breathable interface systems 100, 200, 500, and 600, such as those encountered when a patient rolls in bed or otherwise moves causing compression of the dressing. The additional fluid pathways also reduce the time required to distribute reduced pressure to a tissue site. As detailed below, testing has shown that pressure changes by a reduced pressure source are communicated to the tissue site much more quickly with a dressing configured like that of the breathable interface systems 100, 200, 500, and 600.
[0044] Referring to FIG. 7, an illustrative embodiment of a reduced pressure tissue treatment system 700 incorporating the novel features of the breathable interface system is shown. The reduced pressure tissue treatment system 700 includes a breathable interface system 701 similar to the other breathable interface system described herein, which is applied to a tissue site 702 for treatment. Breathable interface system 100 is fluidly connected to a reduced pressure source 704 by a reduced pressure conduit 112. In certain embodiments, the reduced pressure tissue treatment system 700 may also include a canister 706 for collecting fluid and other non-gaseous exudates extracted from the 702.
- 122017213473 06 Jun 2019 [0045] Referring to FIG. 8, a chart that compares the results of pressure transmission tests on a conventional dressing and a breathable interface system 100 as substantially described above is shown. In the tests, reduced pressure was applied to and water was pumped through each breathable interface system 100 while the breathable interface system 100 was subjected to a range of compressive forces. Pressure measurements were taken on both sides of the compressive forces to determine the performance of each specimen. The results, as shown in FIG. 8, demonstrate that a breathable interface system 100 as described above enables pressure communication across the compressive load to a much greater extent that a conventional dressing.
[0046] The flow of water was set to approximately 20 mls/hr and a compressive force from approximately 0 N to about 500 - 930 N was applied to the conventional dressing and the breathable interface system 100. The y-axis 802 represents the amount of reduced pressure or vacuum measured at either the pump or the dressing/breathable interface system 100. The xaxis 804 represents the duration of time expired from the start of the tests. Line 806 represents the magnitude of the reduced pressure at the pump for the conventional dressing and the line 808 represents the magnitude of the reduced pressure at the opposite side of the dressing. As can be seen from FIG. 8, a compressive force of approximately 900 N was applied to the conventional dressing and the amount of measurable reduced pressure was approximately 0 mm Hg. at the dressing, as shown by line 808. At the start of event 814, the compressive force was released, thus the amount of measurable reduced pressure at the dressing increased to approximately 120 mm Hg. At the end of event 814, a compressive force was applied at a magnitude of 525 N and the amount of measurable reduced pressure dropped back to approximately 0 mm Hg. During this same event, the measurable reduced pressure at the pump side of the dressing, as shown by line 806, stayed at approximately 125 mm Hg. This shows that with a conventional dressing under compressive force, the amount of reduced pressure through the dressing is approximately 0 mm Hg. Similarly, at events 816, 818, and 820, compressive forces were released and reapplied at approximately 250 N. It can be seen from FIG. 8, that essentially the same results followed. Namely, as soon as a compressive force was applied, the measurable amount of reduced pressure through the conventional dressing dropped to 0 mm Hg, or near 0 mm Hg.
[0047] Conversely, line 810 represents the magnitude of the reduced pressure at the pump for the breathable interface system 100 and the line 812 represents the magnitude of the reduced pressure at the opposite side of the dressing. As described above, a compressive force of approximately 900 N was applied to the conventional dressing and the amount of
- 132017213473 06 Jun 2019 measurable reduced pressure was approximately 50 mm Hg at the dressing, as shown by line 812. At the start of event 814, the compressive force was released, thus the amount of measurable reduced pressure at the dressing increased to approximately 120 mm Hg. At the end of event 814, a compressive force was applied at a magnitude of 525 N and the amount of measurable reduced pressure was reduced to approximately 50 mm Hg. During this same event, the measurable reduced pressure at the pump side of the dressing, as shown by line 810, stayed at approximately 125 mm Hg. This shows that with a breathable interface system 100 under compressive force, the amount of reduced pressure is still substantial. Similarly, at events 816, 818, and 820, compressive forces were released and reapplied at approximately 250 N. It can be seen from FIG. 8, that even better results followed. Namely, as soon as a compressive force of approximately 250 N was applied, the measurable amount of reduced pressure through the conventional dressing increased to between approximately 70 mm Hg. and 100 mm Hg.
[0048] Referring to FIG. 9, another chart is shown that compares response times of a conventional dressing and a breathable interface system 100 as substantially described above in FIG. 8 when subjected to intermittent application of reduced pressure under dry conditions. The response times illustrated in FIG. 9 demonstrate that a conventional dressing responds much more slowly than the breathable interface system 100 described above when subjected to these conditions.
[0049] Pressure measurements were taken on both sides of the compressive forces to determine the response times of a conventional dressing compared with the breathable interface system 100 described above. The results, as shown in FIG. 9, demonstrate that a breathable interface system 100 as described above enables faster response times to the intermittent application and release of reduced pressure. The y-axis 902 represents the amount of reduced pressure or vacuum measured at either the pump or the dressing/breathable interface system 100. The x-axis 904 represents the duration of time expired from the start of the tests. Line 906 represents the magnitude of the reduced pressure measured at the pump for the conventional dressing and the line 908 represents the magnitude of the reduced pressure at the opposite side of the dressing. Line 910 represents the magnitude of the reduced pressure measured at the pump for the breathable interface system 100 and the line 912 represents the magnitude of the reduced pressure measured at the opposite side of the breathable interface system 100.
- 142017213473 06 Jun 2019 [0050] As can be seen from FIG. 9, a reduced pressure is cycled on and off between approximately 0 mm Hg and 125 mm Hg. The lines 906 and 910 fairly closely match each other showing that there is little difference of measurable reduced pressure during the tests at the pump side of the dressing/breathable interface system 100 during the cycling of the reduced pressure. At the other side of the dressing, line 908 shows a lag time in achieving the applied reduced pressure at the conventional dressing. This can be seen as line 908 has an arc to its shape representing the gradual building of reduced pressure before it attains full reduced pressure. Conversely, line 912 shows sharp transitions when the reduced pressure is cycled on and off, thus representing that the breathable interface system 100 provides for improved fluid transmission and response to reduced pressure than conventional dressings.
[0051] It should be apparent from the foregoing that an invention having significant advantages has been provided. While the invention is shown in only a few of its forms, it is not just limited but is susceptible to various changes and modifications without departing from the spirit thereof.
Claims (49)
1. A breathable dressing for treating tissue comprising:
an applicator having an aperture;
a first pad section;
a second pad section positioned substantially adjacent to the first pad section;
a drape substantially covering the first pad section, the second pad section, and the applicator;
a fabric layer having a first portion located between the first pad section and the applicator, and a second portion located between the second pad section and the applicator and substantially covering the aperture; and wherein the fabric layer is adapted to receive a reduced pressure to be provided to the aperture.
2. The breathable dressing of claim 1, wherein the first pad section and the second pad section are one single pad.
3. The breathable dressing of claim 2, wherein the single pad is formed from porous foam.
4. The breathable dressing of claim 2, wherein the single pad is formed from multicomponents.
5. The breathable dressing of claim 2, wherein the single pad is multilayered.
6. The breathable dressing of claim 2, wherein the applicator is formed from a flexible material having a sufficiently high moisture vapor transmission rate.
7. The breathable dressing of claim 2, wherein the drape is formed from a flexible material having a sufficiently high moisture vapor transmission rate.
8. The breathable dressing of claim 2, wherein the drape is sealed to the applicator to enclose the single pad and the fabric layer.
9. The breathable dressing of claim 1, further comprising an interface located between the reduced pressure source and at least one of the first pad section and the fabric layer.
- 162017213473 06 Jun 2019
10. The breathable dressing of claim 1, wherein the first pad section and the second pad section are selected from the group consisting of open-cell reticulated foam, sintered polymers, ethylene vinyl acetate, fluoropolymers, polyurethane, polyolefin, vinyl acetate, polyvinyl alcohol, and their copolymers.
11. The breathable dressing of claim 1, wherein the fabric layer is selected from the group consisting of woven fabric, non-woven fabric, polyamide, nylon, polyamide coated with polyurethane, polymeric meshes, non-woven melt blown polymers, and flexible sintered polymers.
12. The breathable dressing of claim 1, wherein the first pad section and the second pad section have a thickness from about 5 mm to about 20 mm.
13. The breathable dressing of claim 1, wherein the fabric layer includes several overlapping layers joined together.
14. A breathable dressing for treating tissue comprising:
an applicator having an aperture;
a first pad section;
a second pad section substantially covering the aperture and positioned substantially adjacent to the first pad section;
a drape substantially covering the first pad section, the second pad section, and the applicator;
a fabric layer having a first portion located between the first pad section and the drape, and a second portion located between the second pad section and the drape; and wherein the fabric layer is adapted to receive a reduced pressure to be provided to the aperture.
15. The breathable dressing of claim 14, wherein the first pad section and the second pad section are one single pad.
16. The breathable dressing of claim 15, wherein the single pad is formed from porous foam.
17. The breathable dressing of claim 15, wherein the single pad is formed from multicomponents.
2017213473 06 Jun 2019
18. The breathable dressing of claim 15, wherein the single pad is multilayered.
19. The breathable dressing of claim 15, wherein the applicator is formed from a flexible material having a sufficiently high moisture vapor transmission rate.
20. The breathable dressing of claim 15, wherein the drape is formed from a flexible material having a sufficiently high moisture vapor transmission rate.
21. The breathable dressing of claim 15, wherein the drape is sealed to the applicator to enclose the single pad and the fabric layer.
22. The breathable dressing of claim 14, further comprising an interface located between the reduced pressure source and at least one of the first pad section and the fabric layer.
23. The breathable dressing of claim 14, wherein the first pad section and the second pad section are selected from the group consisting of open-cell reticulated foam, sintered polymers, ethylene vinyl acetate, fluoropolymers, polyurethane, polyolefin, vinyl acetate, polyvinyl alcohol, and their copolymers.
24. The breathable dressing of claim 14, wherein the fabric layer is selected from the group consisting of woven fabric, non-woven fabric, polyamide, nylon, polyamide coated with polyurethane, polymeric meshes, non-woven melt blown polymers, and flexible sintered polymers.
25. The breathable dressing of claim 14, wherein the first pad section and the second pad section-have a thickness from about 5 mm to about 20 mm.
26. The breathable dressing of claim 14, wherein the fabric layer includes several overlapping layers joined together.
27. The breathable dressing as in any one of claims 1 and 14, wherein the fabric layer has a thickness from about 5 mm to about 20 mm.
28. The breathable dressing as in any one of claims 1 and 14, wherein the fabric layer has a thickness from about 1 mm to about 50 mm.
- 182017213473 06 Jun 2019
29. The breathable dressing as in any one of claims 1 and 14, wherein the first pad section and the second pad section have a thickness from about 5 mm to about 20 mm.
30. A breathable dressing for treating tissue comprising:
an applicator having an aperture;
a porous pad;
a fabric layer located between the porous pad and the applicator and substantially covering the aperture;
a drape sealed to the applicator and substantially enclosing the porous pad and the fabric layer; and wherein the fabric layer is adapted to receive a reduced pressure to be provided to the aperture.
31. The breathable dressing of claim 30, wherein the porous pad is formed from multicomponents.
32. The breathable dressing of claim 30, wherein the porous pad is multilayered.
33. The breathable dressing of claim 32, wherein one layer of the multilayered porous pad is disposed adjacent the fabric layer.
34. The breathable dressing of claim 30, wherein the applicator is formed from a flexible material having a sufficiently high moisture vapor transmission rate.
35. The breathable dressing of claim 30, wherein the drape is formed from a flexible material having a sufficiently high moisture vapor transmission rate.
36. The breathable dressing of claim 30, further comprising an interface located between the reduced pressure source and at least one of the porous pad and the fabric layer.
37. The breathable dressing of claim 30, wherein the porous pad is selected from the group consisting of open-cell reticulated foam, sintered polymers, ethylene vinyl acetate, fluoropolymers, polyurethane, polyolefin, vinyl acetate, polyvinyl alcohol, and their copolymers.
38. The breathable dressing of claim 30, wherein the fabric layer is selected from the group consisting of woven fabric, non-woven fabric, polyamide, nylon, polyamide coated with
- 192017213473 06 Jun 2019 polyurethane, polymeric meshes, non-woven melt blown polymers, and flexible sintered polymers.
39. The breathable dressing of claim 30, wherein the fabric layer includes several overlapping layers joined together.
40. A breathable dressing for treating tissue comprising:
an applicator having an aperture;
a porous pad substantially covering the aperture;
a drape substantially covering the porous pad and the applicator;
a fabric layer located between the porous pad and the drape, wherein the drape is sealed to the applicator to substantially enclose the porous pad and the fabric layer; and wherein the fabric layer is adapted to receive a reduced pressure to be provided to the aperture.
41. The breathable dressing of claim 40, wherein the porous pad is formed from multicomponents.
42. The breathable dressing of claim 40, wherein the porous pad is multilayered.
43. The breathable dressing of claim 42, wherein one layer of the multilayered porous pad is disposed adjacent the fabric layer.
44. The breathable dressing of claim 40, wherein the applicator is formed from a flexible material having a sufficiently high moisture vapor transmission rate.
45. The breathable dressing of claim 40, wherein the drape is formed from a flexible material having a sufficiently high moisture vapor transmission rate.
46. The breathable dressing of claim 40, further comprising an interface located between the reduced pressure source and at least one of the porous pad and the fabric layer.
47. The breathable dressing of claim 40, wherein the porous pad is selected from the group consisting of open-cell reticulated foam, sintered polymers, ethylene vinyl acetate, fluoropolymers, polyurethane, polyolefin, vinyl acetate, polyvinyl alcohol, and their copolymers.
2017213473 06 Jun 2019
48. The breathable dressing of claim 40, wherein the fabric layer is selected from the group consisting of woven fabric, non-woven fabric, polyamide, nylon, polyamide coated with polyurethane, polymeric meshes, non-woven melt blown polymers, and flexible sintered polymers.
49. The breathable dressing of claim 40, wherein the fabric layer includes several overlapping layers joined together.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017213473A AU2017213473B2 (en) | 2007-02-09 | 2017-08-09 | A breathable interface system for topical reduced pressure |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60/900,463 | 2007-02-09 | ||
| AU2008216870A AU2008216870B2 (en) | 2007-02-09 | 2008-02-08 | A breathable interface system for topical reduced pressure |
| AU2013221917A AU2013221917B2 (en) | 2007-02-09 | 2013-08-27 | A breathable interface system for topical reduced pressure |
| AU2015218431A AU2015218431B2 (en) | 2007-02-09 | 2015-08-25 | A breathable interface system for topical reduced pressure |
| AU2017213473A AU2017213473B2 (en) | 2007-02-09 | 2017-08-09 | A breathable interface system for topical reduced pressure |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015218431A Division AU2015218431B2 (en) | 2007-02-09 | 2015-08-25 | A breathable interface system for topical reduced pressure |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2017213473A1 AU2017213473A1 (en) | 2017-08-31 |
| AU2017213473B2 true AU2017213473B2 (en) | 2019-06-27 |
Family
ID=54063319
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015218431A Active AU2015218431B2 (en) | 2007-02-09 | 2015-08-25 | A breathable interface system for topical reduced pressure |
| AU2017213473A Active AU2017213473B2 (en) | 2007-02-09 | 2017-08-09 | A breathable interface system for topical reduced pressure |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015218431A Active AU2015218431B2 (en) | 2007-02-09 | 2015-08-25 | A breathable interface system for topical reduced pressure |
Country Status (1)
| Country | Link |
|---|---|
| AU (2) | AU2015218431B2 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040030304A1 (en) * | 2000-05-09 | 2004-02-12 | Kenneth Hunt | Abdominal wound dressing |
| WO2005123170A1 (en) * | 2004-06-21 | 2005-12-29 | Ethicon, Inc. | Wound dressings for vacuum therapy |
-
2015
- 2015-08-25 AU AU2015218431A patent/AU2015218431B2/en active Active
-
2017
- 2017-08-09 AU AU2017213473A patent/AU2017213473B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040030304A1 (en) * | 2000-05-09 | 2004-02-12 | Kenneth Hunt | Abdominal wound dressing |
| WO2005123170A1 (en) * | 2004-06-21 | 2005-12-29 | Ethicon, Inc. | Wound dressings for vacuum therapy |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017213473A1 (en) | 2017-08-31 |
| AU2015218431B2 (en) | 2017-05-11 |
| AU2015218431A1 (en) | 2015-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11382797B2 (en) | Breathable interface system for topical reduced pressure | |
| US20230201042A1 (en) | Hybrid drape having a gel-coated perforated mesh | |
| US20220062061A1 (en) | Negative pressure wound therapy apparatus | |
| AU2017213473B2 (en) | A breathable interface system for topical reduced pressure | |
| AU2013221917B2 (en) | A breathable interface system for topical reduced pressure | |
| US20220395400A1 (en) | Dressings With Polymer Delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| PC | Assignment registered |
Owner name: 3M INNOVATIVE PROPERTIES COMPANY Free format text: FORMER OWNER(S): KCI LICENSING INC. |
|
| PC | Assignment registered |
Owner name: SOLVENTUM INTELLECTUAL PROPERTIES COMPANY Free format text: FORMER OWNER(S): 3M INNOVATIVE PROPERTIES COMPANY |